Last Updated : May 4, 2024
The latest CADTH Reimbursement Review reports are posted to this page. CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.
| Brand Name | Generic Name | Therapeutic Area | Recommendation Type | Project Status | Date Submission Received Sort descending | Date Recommendation Issued |
|---|---|---|---|---|---|---|
| Eucrisa | crisaborole | atopic dermatitis | Do not reimburse | Complete | ||
| Folotyn | Pralatrexate | Peripheral T-Cell Lymphoma (PTCL) | Reimburse with clinical criteria and/or conditions | Complete | ||
| Lenvima | Lenvatinib | Renal Cell Carcinoma (RCC) | Do not reimburse | Complete | ||
| Velphoro | sucroferric oxyhydroxide | Hyperphosphatemia, end-stage renal disease | Reimburse with clinical criteria and/or conditions | Complete | ||
| Xeljanz | tofacitinib | Ulcerative colitis | Reimburse with clinical criteria and/or conditions | Complete | ||
| Beleodaq | Belinostat | Withdrawn | ||||
| Blincyto | Blinatumomab | Withdrawn | ||||
| Radicava | edaravone | amyotrophic lateral sclerosis | Reimburse with clinical criteria and/or conditions | Complete | ||
| Spinraza | Nusinersen | Spinal Muscular Atrophy | Reimburse with clinical criteria and/or conditions | Complete | ||
| Lutathera | Lutetium Lu 177 dotatate | Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs) | Reimburse with clinical criteria and/or conditions | Complete |
Last Updated : May 4, 2024